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Preimplantation genetic diagnosis (PGD) gives couples who have a high risk of transmitting genetic disorders to their baby the 
chance to have a healthy offspring through embryo genetic analysis and selection. Preimplantation genetic screening (PGS) is 
an effective method to select euploid embryos that may prevent repeated implantation failure or miscarriage. However, how 
and to whom PGS should be provided is a controversial topic. The first successful case of PGD of a human being was reported 
in 1990, and there have been tremendous improvements in this technology since then. Both embryo biopsy and genetic tech-
nologies have been improved dramatically, which increase the accuracy and expand the indications of PGD/PGS. 
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Preimplantation genetic diagnosis (PGD) is an established 
reproductive option for couples with a risk of conceiving a 
baby that is affected with some known genetic disease to 
have an unaffected child, avoiding the termination of preg-
nancy or recurrent miscarriages. PGD is useful in the diag-
nosis of a variety of genetic disorders that are caused by a 
known single gene mutation and chromosome number or 
structure abnormalities, which can be detected in a single 
cell. 
Since 1990, when the first live birth following PGD for a 
recessive X chromosome-linked disease was reported [1], 
PGD has been routinely applied in a variety of genetic dis-
orders, including Tay-Sachs disease, sickle cell anemia, and 
thalassemia, as well as predicting cancer predisposition 
[2–4]. The most frequent single gene disorders detected by 
PGD are beta-thalassemia, cystic fibrosis, myotonic dys-
trophy, Huntington disease, fragile X syndrome [5], 
Comel-Netherton syndrome [6], and endocrine diseases 
(including persistent hyperinsulinemic hypoglycemia of 
infancy, congenital adrenal hyperplasia, and multiple endo-
crine neoplasia type 2A) [7]. Currently, over 10000 babies 
have been born by PGD and preimplantation genetic 
screening (PGS) worldwide [8]. 
In the last 20 years, PGD technology has made a series of 
steps that have improved its accuracy and specificity and 
allowed broader applications for a variety of genetic diseas-
es. There are now multiple biopsy methods for PGD at dif-
ferent embryonic development stages with unique ad-
vantages. Strategies such as whole-genome amplification 
(WGA) have overcome the limitations of minimal template 
DNA from a single biopsied cell. Multiple genes can now 
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be assessed simultaneously, and the accuracy of the method 
has been improved. 
Herein, we reviewed the indications of PGD/PGS recent 
changes in genetic analysis, biopsy methods, WGA methods, 
array platforms and the application of next-generation se-
quencing (NGS) to PGD/PGS programs (Figure 1). 
1  Indications for the application of PGD/PGS 
1.1  PGD for single gene mutations and chromosomal 
disorders 
PGD allows patients who are carriers or who are affected by 
genetic diseases to select unaffected embryos for transfer 
before pregnancy [9]. Single-gene diseases were originally 
the first indication for PGD and aimed to perform genetic 
testing and establish only unaffected pregnancies [1]. Today, 
PGD remains a valid alternative for couples at high risk of 
having a child with monogenetic diseases, i.e., cystic fibro-
sis, beta-thalassemia, Huntington disease, and myotonic 
dystrophy [1,10]. In Europe, more than 7000 cycles were 
performed for single-gene disorders in a total of 60 centers 
until 2010 [11]. Additionally, PGD can help carriers with 
structural chromosome abnormalities, such as reciprocal 
and Robertsonian translocations, inversions, deletions,  
and insertions, have a baby with a normal chromosome 
balance [12]. 
1.2  PGD for cancer patients with a susceptibility gene 
Individuals carrying gene mutations predisposing them to 
hereditary breast/ovarian cancer have concerns about pass-
ing these health problems to their future children [13]. It is 
now feasible to use PGD during the process of in vitro ferti-
lization (IVF) to screen genes associated with high cancer 
risk. Once the mutation site is identified, patients can use 
PGD to select an embryo without familial cancer-predis- 
posing mutations. This procedure has already been per-
formed for several cancers, including the common syn-
dromes of genetic predisposition to breast cancer [14] and 
neurofibromatosis type 1 [15]. 
Drusedau et al. [16] described a universal single-cell 
PGD test for carriers with BRCA1/2 (breast cancer 1/2) 
mutations based on haplotyping 6 (BRCA1) and 8 (BRCA2) 
microsatellite markers in a multiplex polymerase chain re-
action (PCR), which have a clinical pregnancy rate of 
23.5% per embryo transfer. Malcov et al. [17] reported that 
48 PGD cycles in 14 couples resulted in eight pregnancies 
with the cancer predisposition mutation and flanking poly-
morphic markers according to single-cell multiplex nested 
PCR, which confirmed that PGD of cancer predisposition 
genes is a feasible and reliable procedure that is especially 
suitable for infertile carrier couples. More discoveries of 
cancer predisposition mutations will increase the demand 
for PGD to prevent the transmission of disease-related mu-
tations to the next generation. 
1.3  PGD for mitochondrial diseases 
About 15% of mitochondrial or oxidative phosphorylation 
diseases are caused by maternally inherited mitochondrial 
DNA (mtDNA) mutations. Approximately one in 4000 
children are born with an inherited mitochondrial disease in 
the United States [18]. Because of the severe phenotype, the 
limited effective treatments, and the high recurrence risk in 
the offspring of carrier females, couples with this high risk 
often wish to prevent the transmission of these mtDNA dis-
orders to their babies. PGD provides an option to prevent  
 
 
Figure 1  PGD procedures for patients at high risk of transmitting genetic disorders to their baby. 
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the transmission of mtDNA disorders by transferring an 
embryo below the threshold of clinical expression [19]. 
The successful clinical application of PGD of mtDNA 
diseases has been reported in some studies. Steffann et al. 
[20] found that the variation of mitochondrial heteroplasmy 
was fairly small among blastomeres from each embryo but 
the mutation load widely varied among embryos (from zero 
to 100%). They carried out PGD of an mtDNA mutation 
(8993T>G) carrier mother who already had an affected 
child; PGD resulted in a singleton pregnancy with delivery 
of a healthy child. Treff et al. [21] found that, for a carrier 
with 35% 3243A>G mtDNA mutation load, the variation in 
the mutation load within and among embryos varied from 
9% to 90% in oocytes and 7% to 91% in embryos, and the 
mutation loads in the trophectoderm could be predictive of 
the inner cell mass. These researchers selected a male em-
bryo with a 12% mutation load in trophectoderm cells for 
transfer, resulting in the delivery of a boy with tis-
sue-specific mutation loads ranging from undetectable to 
15%. Suzanne et al. [22] showed that PGD of mtDNA dis-
orders was useful when there were oocytes below the 
threshold of the carriers and that the blastomere could be 
representative of the whole embryo in most cases. In this 
study, a healthy son was born from an m.8993T>G carrier, 
which confirmed the possibility of conceiving healthy off-
spring from those couples with mtDNA diseases. Despite 
the above successful case reports, PGD has limited efficacy 
in predicting mtDNA disease because of heteroplasmy and 
genetic bottleneck. PGD may only reduce, but not eliminate, 
the risk of transmitting abnormal mtDNA in subsequent 
generations, and couples should be informed of this during 
the counseling. 
For women with homoplasmic or high levels of hetero-
plasmic mtDNA mutations, oocyte donation is currently the 
only option to have a healthy child. However, oocyte dona-
tion is limited in that there is no genetic link to the mother 
with mtDNA mutations. 
Two other promising approaches, pronuclear and spindle 
transfer, have emerged recently that could be used to avoid 
mitochondrial disease. No successes have been reported in 
human until now. Only one group has reported embryonic 
stem cells derived from a blastocyst embryo by spindle 
transfer [23]. The safety of these technologies requires fur-
ther evaluation. 
1.4  PGD for human leukocyte antigen (HLA) matching 
The use of PGD for combined analysis of mutations and 
HLA matching was reported for the first time in 2001 [24]. 
It enables the birth of an unaffected child with the closest 
HLA match to his (her) affected sibling. As a donor, the 
newborn baby could provide stem cells or some human tis-
sue to the sibling in the transplant [25]. Numerous families 
have successfully used PGD for HLA matching to treat the 
affected child. In 2004, a group from Israel reported the 
successful cord blood transplantation to a Fanconi anemia 
patient from his HLA-matched sibling, who was born after 
PGD that included mutation analysis for Fanconi anemia 
and HLA typing [26]. 
Based on the data from the European Society of Human 
Reproduction and Embryology, more than 500 PGD-HLA 
cycles have been performed until October 2010 [11]. The 
most common indication of HLA-matching is PGD com-
bined with the exclusion of β-thalassemia and/or sickle-cell 
syndromes (~66% of cycles performed) [11]. 
1.5  PGS for couples with a special history 
Because the first deliveries after embryo transfer following 
PGS were reported in 1995 [27], the procedure and tech-
nologies for aneuploidy detection have become readily 
available for clinical practice. Most of the early pregnancy 
losses are believed to be attributed to aneuploidy [28]. At 
present, PGS can be offered to couples with one or more of 
the following indications: (i) the woman with advanced 
maternal age (>35 and <40 years), (ii) a history of recurrent 
miscarriage (two occurrences or more), (iii) repeated im-
plantation failure (more than three occurrences), and (iv) 
severe male factor infertility [29]. With the development of 
chromosome screening methods, blastocyst freezing, and 
trophectoderm biopsy techniques, women with advanced 
maternal age (>35 years of age) can use single-embryo 
screening for transfer to increase the birth rate [30]. Despite 
the above advances, problems still remain, such as how to 
optimize the procedure to safely offer the technique to pa-
tients and which group of patients would benefit more from 
routine biopsy [31]. 
2  Genetic analysis methods in PGD 
2.1  PGD using PCR 
Single-cell PCR was the first application used in PGD for 
two couples with a risk of transmitting adrenoleukodystro-
phy and X-linked mental retardation. Through DNA ampli-
fication of a Y chromosome-specific sequence, the female 
patients were confirmed to carry normal female twins [1]. 
Since then, the PCR method has been used to diagnose 
many single gene diseases during assisted reproductive 
technology processes. 
However, using PCR for PGD also has difficulties such 
as contamination, amplification failure because of low- 
quantity DNA template, and allele drop-out (ADO) in het-
erozygous loci [32]. To obtain a more accurate diagnosis 
and simultaneously exclude ADO and contamination, the 
co-amplification of several loci by multiplex PCR is rec-
ommended [33,34]. Two upstream and two downstream 
markers are preferably applied within 1 Mb of the disease 
mutation to reduce the risk of recombination events. If there 
are no linked markers available and the multiplex PCR is 
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difficult, an alternative method to identify ADO is to biopsy 
two cells on day 3 or two cell clusters on day 5 with inde-
pendent analysis [35–37]. 
2.2  PGD/PGS using fluorescence in situ hybridization 
(FISH) 
The applications of FISH made the analysis of aneuploidies 
in embryos a reality. Screening a large number of chromo-
somes significantly increases the live-birth rate for mothers 
with an advanced maternal age [38]. The major limitations 
of FISH are the limited number of tested chromosomes that 
can be analyzed simultaneously and the technical difficulty 
of nuclear fixation and staining. Poor spreading could result 
in low-quality nuclei staining or even the loss of chromatin, 
decreasing the accuracy of the diagnosis [39,40]. Indeed, 
misdiagnosis can also result from overlapping signals, split 
signals, cross-hybridization, and polymorphisms [41]. How- 
ever, some of these limitations might be overcome by using 
different strategies. To improve FISH accuracy, additional 
probes in the same chromosome could be applied to dou-
ble-check ambiguous signals [42]. 
2.3  Array comparative genomic hybridization (CGH) 
and single nucleotide polymorphism (SNP) applications 
in PGD or PGS 
In recent years, several approaches for 24-chromosome 
analysis coupled with WGA have been developed to im-
prove clinical outcomes. The first of these approaches to be 
applied in PGS was CGH [43], in which the genome of the 
interested cell is hybridized with a reference genome on a 
slide. More recently, array CGH has emerged, which pro-
vides high resolution and a rapid and simple procedure. 
There are two types of array platforms: CGH and SNP [44]. 
The advances of the array platforms could increase the reli-
ability and stability of diagnosis by PGS, but the approaches 
need to be optimized for future applications. 
The first successful application of array CGH using sin-
gle cells, such as a single lymphoblast, fibroblast, and blas-
tomere [45], suggested that it was the most appropriate 
method because of its high efficiency, chromosome detec-
tion, and time of analysis. Simpson et al. also pointed out 
that array CGH was the preferred diagnostic approach to 
assess 24 chromosomes for genetic screening in IVF treat-
ment [46]. 
2.4  Next-generation sequencing (NGS) in PGD or PGS 
Current approaches to evaluate the genomic state in PGD 
have significant limitations, such as providing limited reso-
lution or restricted information (PCR for some loci, FISH 
for a few chromosomes, array for aneuploidy screening), 
which prevent the detection of aneuploidy and SNPs associ-
ated with Mendelian diseases and de novo mutations [47]. 
Therefore, it is necessary to establish a straightforward and 
reliable approach that can simultaneously analyze all men-
tioned PGD/PGS indications. Advances in WGA and DNA 
sequencing have made it practical to generate huge amounts 
of data by high-throughput NGS technologies. 
The first study reported the extensive preclinical valida-
tion and assessed the accuracy of NGS-based comprehen-
sive aneuploidy screening with single cells. In this study, 
NGS was demonstrated as a robust high-throughput meth-
odology ready for clinical application in reproductive medi-
cine, with the potential advantages of reduced costs and 
enhanced precision [48]. 
Genomics analysis in PGD/PGS using NGS, microarrays, 
or real-time PCR is often limited by the small amount of 
template available, which could rely on WGA from a single 
cell to generate enough DNA template for sequencing. Mul-
tiple displacement amplification could provide improve-
ments over PCR-based methods [49], but it still has consid-
erable bias. 
A group from Harvard University developed a new 
WGA method, multiple annealing and looping-based ampli-
fication cycles (MALBAC), which showed high uniformity 
across the genome and achieved 93% genome coverage for 
a single human cell at 25× mean sequencing. MALBAC has 
been used to sequence a single circulating tumor cell [50], 
single sperm cells [51], and single oocyte cells [52]. 
Hou et al. [52] estimated the sensitivity and specificity of 
aneuploidy detection with different resolutions and showed 
that, for sub-megabase resolution (0.5 Mb), single-cell se-
quencing based on MALBAC achieves 94.8% sensitivity 
and 97.5% specificity, which is superior to most of the 
available CGH and SNP array technologies and allows ac-
curate and cost-effective embryo selection for IVF. With 
MALBAC’s significantly improved coverage uniformity 
[53], maternal point mutations can be detected with high 
sensitivity and accuracy. This approach can be applied to 
both polar bodies and blastocyst stage embryos, and it can 
detect all aneuploidies and gene mutations. Further im-
provements in the technology robustness and workflow, as 
well as finding new ways to reduce costs, will promote the 
use of NGS in clinical diagnosis. Eventually, the advantages 
of NGS will benefit PGD/PGS patients [54]. 
Perhaps many people want to use PGD to select embryos 
with a desired phenotype. In 2007, scientists in Europe 
identified the SNPs that are associated with a host of physi-
cal traits such as eye color, hair color, and freckles [55]. 
Currently, most clinics do not offer PGD for these features; 
however, from a technological point of view, it is a possible 
application in the future [25]. 
The authors believe that PGD should only be provided to 
couples with genetic diseases or a known serious disease, 
but not to anyone who expects a “designer baby.” PGD 
technologies require development to a high level to achieve  
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this goal. First, currently we cannot determine the relation-
ship between most genotypes and phenotypes and the role 
of certain genotypes in human evolution. Second, we cannot 
distinguish the bad from the good genes in human beings. 
Third, PGD methods are performed on embryos in vitro; 
even using the so-called non-invasive technology, the 
long-term safety of this technology is still a concern. 
Therefore, PGD techniques cannot be used for “designer 
babies.” Governments should develop strict laws and regu-
lations to prevent the abuse of this technology. 
3  Cell samples provided for PGD 
The first step in preimplantation genetic testing is to obtain 
DNA from the oocyte or embryo. Currently, there are three 
potential methods according to the source of DNA collec-
tion: polar body biopsy, blastomere biopsy (aspiration) from 
the 6- to 8-cell cleaving embryos, and trophectoderm biopsy 
from the blastocyst. The optimal biopsy stage should be 
carefully considered. 
The oocyte genotype can be deduced by analyzing the 
first and second polar body [52]. Polar body biopsy is less 
invasive and requires a longer time for the analysis than 
other methods, but it cannot be used to detect aneuploidies 
and mutations or aneuploidies inherited from the father and 
de novo mutations arising from mitosis. 
Embryo biopsy is a more widely used approach because 
both paternal and maternal alleles can be detected. Embryo 
biopsy at the cleavage stage (6- to 8-cell stage) with the 
removal of one or two cells is the most common approach 
for PGD, which provides adequate samples but is detri-
mental to the embryo. About two of every five reproductively 
competent embryos will lose their ability to develop [56]. 
Blastomeric analysis is prone to error due to high ADO 
and mosaicism [57,58]. Blastocyst biopsy has been widely 
applied in PGD clinics in recent years because it is highly 
effective for the PGD of monogenic diseases [59]. Current 
data suggest that trophectoderm biopsy may not adversely 
impact embryos. In addition, blastocyst biopsy provides 
primary DNA templates, which would improve the sensitiv-
ity and specificity of PGD. However, the time for molecular 
diagnosis is limited. Thus, blastocyst freezing would be 
necessary. Fortunately, clinical outcomes indicated that 
fresh IVF and cryopreserved embryo transfer cycles were 
equivalent [59]. Currently, the blastocyst stage is the opti-
mal stage to perform biopsies for preimplantation genetic 
testing [56,60]. 
As for PGD with sperm, a group from France recently 
reported the first birth originating from couples with a male 
translocation carrier. By discontinuous gradient centrifuga-
tion, the proportion of unbalanced spermatozoa decreased 
from 63.6% to 52.3% in this patient [61]. 
4  Misdiagnosis by PGD 
Notably, it is important to note that PGD is not as accurate 
as prenatal testing with chorionic villi sampling, amniocen-
tesis, or testing of umbilical cord blood. Therefore, each 
patient must receive follow-up care, and are recommended 
prenatal diagnosis. 
The causes of misdiagnosis include confusions of em-
bryo and sample number (marking error, unclear, erased), 
the wrong embryo for transfer or thawing, maternal (cumu-
lus cells) or paternal (sperm) contamination, ADO (one 
study reported 11.9% [62]), using incorrect and inappropri-
ate probes or primers, probe or primer failure, and chromo-
somal mosaicism in cleavage-stage and blastocyst embryos. 
Unprotected sexual intercourse has been mentioned as a 
cause of adverse outcomes not related to PGD analysis er-
rors [63]. The majority of these causes could be prevented 
by improved procedures, such as careful operation, dou-
ble-check, sufficient pre-experimentation, and establishing a 
standard operation procedure. However, an exact diagnosis 
from a single cell is still a great challenge, and the risk of 
misdiagnosis cannot be completely eliminated. 
The data collected by the European Society of Human 
Reproduction and Embryology (ESHRE) PGD Consortium 
indicated that the misdiagnosis was 0.15% for PCR-based 
cycles and 0.06% for FISH-based PGD cycles. However, 
these numbers may not reflect the reality. For example, 
some embryo transfer cycles have no follow-up records (no 
pregnancy or birth), and the majority of untransferred sur-
plus embryos were not re-analyzed [11]. 
5  Pregnancy rate with PGD 
The average pregnancy rate per oocyte retrieval cycle was 
about 23.04% (range, 0 to 100%) according to the 12th an-
nual data from the ESHRE PGD Consortium [11]. Research 
about the PGD of monogenic diseases showed that the 
pregnancy rate per oocyte retrieval cycle reached 60% with 
an implantation rate of 50% [59]. Another group obtained a 
clinical pregnancy rate of 60.3% per transfer cycle with an 
implantation rate of 53.5% [64]. 
6  Summary 
Reproductive medicine, a quickly developing field of medi-
cine, is the discipline that can directly apply most of the 
advances from genomics to clinical treatment by providing 
effective strategies for personalized fertility and sterility 
treatment. PGD represents a valuable option for patients 
with the high risk of transmitting an inherited disorder to 
their offspring. PGD can be applied for any Mendelian dis-
order with known locations. Moreover, combined with 
linkage marker (short tandem repeats, SNPs, and haplotypes) 
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analysis, PGD can also be used if the mutation site is un-
known. So far, more than 300 different conditions have 
been tested with high accuracy. As more genetic markers 
associated with diseases are identified, our ability to predict 
genetic disease will significantly increase. The era of PGD 
with deep sequencing is coming and will benefit more cou-
ples with genetic disorders or infertility problems. Addi-
tionally, PGD with deep sequencing also has the advantages 
of high sensitivity and specificity to detect both point muta-
tions and aneuploidy, and it is cost efficient. 
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